Alnylam Pharmaceuticals

back to Directory

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals logo

Founded
2002

Patents
56

Clinical Trials
49

Publications
393

Alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as RNA interference, or RNAi. With RNAi technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today&s;s medicines.

Posts Mentioning This Company

11 Biopharma Trends to Watch in 2024

2023 has marked a remarkable year of technological advancements in drug discovery and biotechnology. Ironically, the elation from a kaleidoscope of technological and scientific advances is in stark contrast with the overall industry’s economic performance—it was also a rough year for biopharma overall. There are signs that 2024 might be better …

Beyond Traditional Medicine: Exploring the Revolutionary Therapies Transforming Patient Care

Biotechnology has revolutionized the healthcare industry, and with the increasing demand for advanced therapies, the focus has shifted towards innovative therapeutic modalities. In this blog article, we will explore some of the cutting-edge therapeutic modalities that have the potential to transform patient care.